New drug aims to keep platelets up during breast cancer chemo

NCT ID NCT07647029

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests whether the drug hetrombopag can prevent dangerously low platelet counts caused by chemotherapy in breast cancer patients at high risk. About 126 participants will be split into three groups: one getting no preventive drug, one taking hetrombopag continuously for two chemo cycles, and one taking it for 14 days each cycle. The main goal is to see if the drug reduces the number of patients who develop moderate to severe low platelets.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hetrombopag (a drug to boost platelet counts)
What this could lead to: If it works, this could point toward a way to prevent severe low platelet counts during chemotherapy, helping breast cancer patients complete their treatment on schedule.
What could go wrong: This is a small, early-phase trial (126 people) that has not started recruiting yet. The drug may not reduce low platelet events as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PATIENTS AT HIGH RISK OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CTIT)

More trials for these conditions

Other studies related to the condition(s) this trial covers.